Pancreatic Cancer Research

ResearcherUniversity of MissouriActive in the last 2 years

Kuirong Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2849-5450; OpenAlex author ID A5029987881. Sources: ClinicalTrials.gov.

Their work

Papers
91 (first author 0, last author 36)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
181
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 5 papers · 2014: 4 papers · 2015: 1 paper · 2016: none · 2017: 8 papers · 2018: 6 papers · 2019: 6 papers · 2020: 9 papers · 2021: 13 papers · 2022: 8 papers · 2023: 3 papers · 2024: 4 papers · 2025: 11 papers, 1 trial · 2026: 10 papers

Papers 50 of 91

  1. Bridging the innovation-evidence chasm: a critical appraisal and roadmap for robotic pancreatic cancer surgery. Last author DOI 10.1007/s11701-026-03284-x↗
  2. Tumor cell derived CCL20 exacerbates the immunosuppressive microenvironment by recruiting CCR6+ Tregs in pancreatic cancer. Last author DOI 10.1016/j.canlet.2026.218290↗
  3. Single-cell spatial transcriptional profiling of pancreatic ductal adenocarcinoma uncovers key immune-modulating and pro-metastatic mechanisms. Last author DOI 10.1016/j.canlet.2026.218613↗
  4. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  5. First-line nanoparticle polymeric micellar paclitaxel with gemcitabine in metastatic pancreatic cancer: a single-arm, prospective, and exploratory study. Co-author DOI 10.1093/gastro/goag034↗
  6. Long-term outcomes of upfront pancreatectomy with venous resection for pancreatic cancer: a single-center, retrospective analysis. Last author DOI 10.1097/js9.0000000000003617↗
  7. Identification of a Novel Chemokine-Related Long Noncoding RNA Risk Model Via Comprehensive Prognostic and Immune Analyses in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002630↗
  8. Ferroptosis in cancer toward molecular insights and clinical translation in pancreatic cancer. Last author DOI 10.1186/s12943-025-02567-5↗
  9. Post-surgery weight changes in pancreatic cancer: a prospective study on factors and survival impact. Co-author DOI 10.1186/s12957-026-04202-z↗
  10. Co-evolution of Oncogenic KRAS Signaling and LILRB high Macrophages Drives Pancreatic Cancer Recurrence Co-author DOI 10.64898/2026.03.05.709991↗
  11. Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance. Co-author DOI 10.1016/j.seminoncol.2025.152338↗
  12. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  13. Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT… Last author DOI 10.1038/s41416-025-03061-x↗
  14. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  15. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01426-y↗
  16. Editorial Expression of Concern to: The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Last author DOI 10.1038/s41419-025-07740-8↗
  17. Shared HLA-Bound Neoepitopes Are New Targets for Pancreatic Cancer Immunotherapy. Co-author DOI 10.1158/1078-0432.ccr-24-4368↗
  18. The feasibility and potential benefits of administering adjuvant chemotherapy in resected pancreatic cancer patients unable to promptly remove intraperitoneal … Last author DOI 10.1186/s12885-025-14262-1↗
  19. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Co-author DOI 10.1186/s12943-025-02326-6↗
  20. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Co-author DOI 10.1186/s12967-025-06581-5↗
  21. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Last author DOI 10.1200/jco.24.00287↗
  22. Peptidase inhibitor 16 promotes proliferation of pancreatic ductal adenocarcinoma cells through OASL signaling. Last author DOI 10.1002/mc.23699↗
  23. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  24. A Targeted Octahedral DNA Nanostructure Co-delivers siME3 and Doxorubicin to Enhance Collateral Lethality in ME2-Deficient Pancreatic Cancer. Last author DOI 10.1021/acs.nanolett.4c05123↗
  25. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Last author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  26. Translation and validation of the Pancreatic Cancer Disease Impact score for Chinese patients with pancreatic cancer: A methodological and cross-sectional stud… Co-author DOI 10.1016/j.apjon.2023.100209↗
  27. The SIX1/LDHA Axis Promotes Lactate Accumulation and Leads to NK Cell Dysfunction in Pancreatic Cancer. Last author DOI 10.1155/2023/6891636↗
  28. Comprehensive prognostic and immune analysis of a glycosylation related risk model in pancreatic cancer. Co-author DOI 10.1186/s12885-023-11725-1↗
  29. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  30. A histopathological study of artery wall involvement in pancreatic cancer surgery. Co-author DOI 10.1007/s00423-022-02689-0↗
  31. The distinct genetic features of pancreatic cancer in Chinese population. Co-author DOI 10.1016/j.ebiom.2022.103960↗
  32. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Last author DOI 10.1186/s12943-022-01599-5↗
  33. Correction: CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing. Last author DOI 10.1186/s12943-022-01636-3↗
  34. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Last author DOI 10.1186/s13578-022-00833-3↗
  35. Identification of genomic instability related lncRNA signature with prognostic value and its role in cancer immunotherapy in pancreatic cancer. Co-author DOI 10.3389/fgene.2022.990661↗
  36. Suppressive effect of YY1-mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2022.13577↗
  37. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  38. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer. Co-author DOI 10.1007/s10637-021-01114-5↗
  39. Survival prediction after upfront surgery in patients with pancreatic ductal adenocarcinoma: Radiomic, clinic-pathologic and body composition analysis. Co-author DOI 10.1016/j.pan.2021.02.009↗
  40. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… Last author DOI 10.1016/j.pan.2021.05.300↗
  41. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  42. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  43. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Co-author DOI 10.1126/sciadv.abh2724↗
  44. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Last author DOI 10.1155/2021/6530298↗
  45. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Last author DOI 10.1186/s12943-021-01333-7↗
  46. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13046-021-02063-w↗
  47. Development and validation of a ferroptosis-related prognostic model in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-139597/v2↗
  48. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fimmu.2021.800268↗
  49. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  50. Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival. Co-author DOI 10.1002/cam4.3559↗

Trials 1

  1. Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Principal investigator NCT07277452↗

Closest collaborators

The 25 strongest of 181 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 49 shared papers, 2011–2025 · strength 4.79
  2. Zipeng Lu · 39 shared papers, 2011–2026 · strength 4.31
  3. Jishu Wei · 24 shared papers, 2011–2026 · strength 2.87
  4. Min Tu · 17 shared papers, 2013–2026 · strength 2.42
  5. Qun Chen · 17 shared papers, 2019–2025 · strength 2.41
  6. Wentao Gao · 24 shared papers, 2011–2026 · strength 2.38
  7. Wanli Ge · 15 shared papers, 2018–2025 · strength 2.03
  8. Lingdi Yin · 13 shared papers, 2017–2026 · strength 1.97
  9. Pengfei Wu · 16 shared papers, 2013–2026 · strength 1.96
  10. Yi Miao · 15 shared papers, 2013–2025 · strength 1.95
  11. Xumin Huang · 14 shared papers, 2019–2026 · strength 1.93
  12. Junli Wu · 18 shared papers, 2011–2026 · strength 1.89
  13. Lingdong Meng · 13 shared papers, 2019–2025 · strength 1.83
  14. Hao Yuan · 16 shared papers, 2017–2025 · strength 1.79
  15. Yunpeng Peng · 14 shared papers, 2013–2025 · strength 1.69
  16. Peng Shen · 12 shared papers, 2019–2025 · strength 1.62
  17. Jingjing Zhang · 17 shared papers, 2013–2025 · strength 1.50
  18. Guodong Shi · 14 shared papers, 2017–2025 · strength 1.40
  19. Baobao Cai · 14 shared papers, 2013–2022 · strength 1.32
  20. Kai Zhang · 8 shared papers, 2019–2024 · strength 1.09
  21. Chunyi Hao · 1 shared paper, 1 shared trial, 2025–2026 · strength 1.03
  22. Taoyue Yang · 7 shared papers, 2021–2022 · strength 0.87
  23. Kai Zhang · 5 shared papers, 2020–2025 · strength 0.83
  24. Yang Feng Wu · 7 shared papers, 2017–2025 · strength 0.83
  25. Guangfu Wang · 5 shared papers, 2019–2025 · strength 0.77

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.